BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Glioblastoma and glioma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for glioblastoma: 125 (105 sponsors; 16 newly posted in the last 180 days, 6 stopped in the last 180 days; 10 new-entrant sponsors). Momentum score 9.2, rank 76 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 4, Phase 1 36, Phase 2 60, Phase 3 11, Phase 4 2, N/A 12.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
GT Medical Technologies, Inc.3NA 1, P3 1, P4 100
Telix Pharmaceuticals (Innovations) Pty Limited TLX2P3 1, P1 100
Aivita Biomedical, Inc.1P3 100
Beijing Pearl Biotechnology Limited Liability Company1P3 100
CarThera1P3 100
Everfront Biotech Co., Ltd.1P3 100
Laminar Pharmaceuticals1P3 100
NaviFUS Corporation1P3 101
NovoCure GmbH NVCR1P3 100
Nuvation Bio Inc. NUVB1P3 100
TVAX Biomedical1P3 100
Novartis Pharmaceuticals NVS4P1 3, P4 100
Beijing Biotech3P1 2, P2 103
Alpheus Medical, Inc.2P1 1, P2 110
Beijing Tricision Biotherapeutics Inc2P2 1, P1 110
Black Diamond Therapeutics, Inc. BDTX2P2 200
Boston Scientific Corporation BSX2NA 1, P1 111
BPGbio2P2 1, NA 110
Cerenome CNSY2P2 1, P1 101
ImmunityBio, Inc. IBRX2P2 210
Myosin Therapeutics Inc.2P2 211
Neonc Technologies, Inc. NTHI2P2 202
Novelwise Pharmaceutical Corporation2P2 200
NuvOx LLC NUOX2P2 1, NA 100
Philogen S.p.A.2P2 200

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Neonc Technologies, Inc. NTHINCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaGlioblastoma Multiformeactive not recruiting49
2026-12 est.P1/P2Sapience TherapeuticsNCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brainactive not recruiting125
2026-12 est.P1/P2In8bio Inc. INABNCT05664243 A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance TemozolomGlioblastomaactive not recruiting4
2026-12-31 est.P1/P2Aveta Biomics, Inc.NCT06011109 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and BevacizumabGlioma; Glioblastoma Multiformeactive not recruiting30
2026-12-31 est.P3NaviFUS CorporationNCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) UGlioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Turecruiting32
2026-12-31 est.P1/P2Hangzhou Hanx Biopharmaceuticals, Ltd.NCT06703255 A Phase 2 Study of HX301 in Patients with High-grade GilomaGliomarecruiting72
2027-01 est.P2ImvaxNCT04485949 A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaGlioblastomaactive not recruiting99
2027-02 est.P2Eli Lilly and Company LLYNCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyGliomaactive not recruiting45

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P1/P2Myosin Therapeutics Inc.NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM PatientsGlioblastoma (GBM)recruiting36
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06598787 A Study of BL-B01D1 in Patients With Recurrent GlioblastomaRecurrent Glioblastomarecruiting20
2026-10 est.P1/P2Philogen S.p.A.NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomarecruiting226
2026-10 est.P1/P2Laminar PharmaceuticalsNCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid TumorsHigh-grade Glioma; Solid Tumor, Unspecified, Childrecruiting28
2026-09-30 est.P2Cantex PharmaceuticalsNCT05986851 Azeliragon in MGMT Unmethylated GlioblastomaGlioblastomaactive not recruiting30
2026-08-25 est.P2BPGbioNCT04752813 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)Glioblastoma; Glioblastoma Multiformeactive not recruiting50
2026-08-16 est.P2JenKem Technology Co., Ltd.NCT06595186 JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)Glioblastoma Multiforme (GBM)recruiting25
2026-06 est.P2Philogen S.p.A.NCT06336291 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceGlioblastomaactive not recruiting90
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-27P1/P2Genenta Science SAENNCT03866109 A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGlioblastoma Multiformeterminated25

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "glioblastoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.